Related Experiment Videos
Heparin cofactor II: a new marker for pre-eclampsia
J Bellart1, R Gilabert, L Cabero
1Unitat de Medicina Materno-fetal, Hospital Universitari de Tarragona Joan XXIII, Universitat Rovira i Virgili, Spain. jbellarta@meditex.es
Summary
Plasma levels of heparin cofactor II were lower in pregnant women with pre-eclampsia. This finding may help differentiate pre-eclampsia from other hypertensive disorders in pregnancy.
Area of Science:
- Obstetrics and Gynecology
- Hematology
- Cardiovascular Physiology
Background:
- Hypertensive disorders in pregnancy, including pre-eclampsia, pose significant risks.
- Accurate differential diagnosis between various hypertensive conditions is crucial for appropriate management.
- Heparin cofactor II (HC-II) is a key regulator of thrombin generation.
Purpose of the Study:
- To investigate plasma levels of heparin cofactor II (HC-II) in pregnant women with different hypertensive conditions.
- To assess the potential of HC-II levels in differentiating pre-eclampsia from other forms of hypertension during pregnancy.
Main Methods:
- Plasma samples were collected from pregnant women in their third trimester and 72 hours postpartum.
- Participants were categorized into normotensive, essential hypertension, gestational hypertension, and pre-eclampsia groups.
- Plasma concentrations of heparin cofactor II were measured using established biochemical assays.
Main Results:
- A significant depression in plasma heparin cofactor II levels was observed in the pre-eclampsia group compared to normotensive and other hypertensive groups.
- No significant differences in HC-II levels were noted between normotensive, essential hypertension, and gestational hypertension groups.
Conclusions:
- Reduced plasma heparin cofactor II levels are associated with pre-eclampsia during late pregnancy.
- Plasma HC-II levels may serve as a useful biomarker for the differential diagnosis of non-proteinuric hypertension versus pre-eclampsia.